Brief: Femasys Announces FDA Approval Of Its Ide For The Pivotal Clinical Trial Of FemBloc Permanent Birth Control, A Non-Surgical Alternative For Women
26/06/2023 13:22
June 26 (Reuters) - Femasys Inc FEMY.O :
* FEMASYS ANNOUNCES FDA APPROVAL OF ITS IDE FOR THE PIVOTAL
CLINICAL TRIAL OF FEMBLOC PERMANENT BIRTH CONTROL, A
NON-SURGICAL ALTERNATIVE FOR WOMEN
* FEMASYS INC - PIVOTAL CLINICAL TRIAL TO BEGIN IN Q3 OF
2023
Source text for Eikon: ID:nGNX6z1jVJ
Further company coverage: FEMY.O
((Reuters.Briefs@thomsonreuters.com;))